Hologic said this week that Carl Hull will retire from his role as senior vice president and general manager of diagnostics effective on Feb. 15.

Hull previously served as chairman, president, and CEO of Gen-Probe until that company was acquired by Hologic last year in a deal worth an estimated $3.7 billion (PCR Insider, 5/3/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.